(19)

(11)

EP 3 347 012 A1

(12)

(43) Date of publication: 18.07.2018 Bulletin 2018/29 (21) Application number: 16845102.9 (22) Date of filing: 09.09.2016

(51) International Patent Classification (IPC):  A61K 31/435(2006.01) A61P 25/14(2006.01) A61P 25/24(2006.01) A61P 25/00(2006.01) A61P 25/18(2006.01) A61P 25/28(2006.01) (86) International application number: PCT/US2016/050907 (87) International publication number: WO 2017/044714 (16.03.2017 Gazette 2017/11)

(84) Designated Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR Designated Extension States: BA ME Designated Validation States: MA MD (30) Priority: 11.09.2015 US 201562217081 P 17.06.2016 US 201662351382 P (71) Applicant: Chase Pharmaceuticals Corporation Washington, DC 2006-1236 (US)	(72) Inventors: CHASE, Thomas N. Washington, District of Columbia 20006-1236 (US) CLARENCE-SMITH, Kathleen E. Washington, District of Columbia 20006-1236 (US) (74) Representative: Schlich, George et al Schlich 9 St Catherine's Road Littlehampton, West Sussex BN17 5HS Littlehampton, West Sussex BN17 5HS (GB)